Venetoclax with hypomethylating agents for older or unfit adults with FLT3-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of medicines (venetoclax and a hypomethylating agent) for people with acute myeloid leukemia (AML) who have a FLT3 mutation. It may be an option for older adults or those who cannot tolerate intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years or older, or younger than 60 but your doctor thinks a less intensive treatment is better for you.
- You have been diagnosed with acute myeloid leukemia (AML) that has a FLT3 mutation.
- You have not had any prior treatment for AML except for limited emergency treatments to control white blood cell counts.
- You have not been treated with 'hypomethylating agents' (like azacitidine or decitabine) or FLT3 inhibitors before.
- Your liver and kidney function tests are within acceptable limits.
- If you can become pregnant or father a child, you must agree to use effective contraception during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This trial tests whether a shorter course of venetoclax (a targeted pill) combined with azacitidine (a chemotherapy drug) works as well as the standard longer course for older or frail adults with acute myeloid leukemia (AML). It aims to reduce side effects while keeping the treatment effective.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.